Cardiovascular

Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes?

Freek Verheugt
Freek Verheugt

Shamir Mehta of McMaster University told Audio Medica in Stockholm about the OASIS-5/MICHELANGELO results comparing the new anti-thrombotic therapy, fondaparinux, with enoxaparin among patients with acute coronary syndromes. For a comment on Shamir Mehta’s presentation at the ESC meeting, Audio Medica questioned Freek Verheugt of Nijmegen.
Shamir Mehta:
Freek Verheugt:

Click here for all the interviews from ESC 2005

Similar Interviews

  • Audio Journal of Cardiovascular Medicine 11.3, October 2005
  • Reporting from: European Society of Cardiology Congress September 3-7, 2005, Stockholm Scientific Editors: Michael Petch, Papworth Hospital, Cambridge Man Fai Shiu, Walsgrave Hospital, Coventry James

  • Audio Journal of Cardiovascular Medicine: September 5th 2006
  • Shamir Mehta

  • Single Agent Bivalirudin Better for Acute Coronary Syndromes
  • Gregg Stone, Columbia University Medical Center, New York American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta A superiority for

    Post a comment

    Subscribe to Audio Medica Podcast